Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Fulcrum Therapeutics, Inc. (FULC) had Stock-Based Compensation of $9.40M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-19.59M |
|
-- |
|
-- |
|
$21.86M |
|
$-21.86M |
|
$2.26M |
|
$-19.59M |
|
$-19.59M |
|
$-19.59M |
|
$-19.59M |
|
$-19.59M |
|
$-19.59M |
|
$-21.86M |
|
$-21.51M |
|
62.60M |
|
62.60M |
|
$-0.31 |
|
$-0.31 |
|
| Balance Sheet Financials | |
$205.86M |
|
$3.17M |
|
$8.99M |
|
$214.86M |
|
$11.63M |
|
-- |
|
$4.86M |
|
$16.49M |
|
$198.37M |
|
$198.37M |
|
$198.37M |
|
54.11M |
|
| Cash Flow Statement Financials | |
$-43.27M |
|
$31.77M |
|
$0.36M |
|
$59.41M |
|
$48.28M |
|
$-11.13M |
|
|
Stock-Based Compensation |
$9.40M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
17.70 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-43.42M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-9.88% |
|
-9.88% |
|
-9.12% |
|
-9.88% |
|
$3.67 |
|
$-0.69 |
|
$-0.69 |
|